After racking up more than $200,000 in student loans, surgery resident Daisy Sanchez, MD, celebrated her last payment and ...

Mergers and acquisitions grabbed the spotlight in the biotech sector once again this week after BioMarin BMRN agreed to acquire Inozyme Pharma INZY. Meanwhile, other pipeline and ...

Mergers and acquisitions grabbed the spotlight in the biotech sector once again this week after BioMarin BMRN agreed to ...

The FDA gave Pfizer and Moderna until May 17 to propose changes to the labels of their COVID-19 vaccines or challenge the ...

The approval of Nuvaxovid for use in older and high-risk adults will generate around $175 million in milestone payments from ...

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years ...

Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating ...

The US Food and Drug Administration has fully approved a new COVID vaccine option specifically targeting high-risk individuals, including seniors. The protein-based Nuvaxovid vaccine, produced by ...

Novavax's shot is now fully approved in the U.S. Since 2022, the vaccine has been used under an emergency use authorization.

The FDA has approved the Novavax COVID-19 vaccine, called Nuvaxovid, mainly for adults 65 or older, but people ages 12 to 64 with medical conditions that increase their risk of serious illness from ...

Plus: FDA approves COVID-19 vaccine developed in Gaithersburg; Robert Frost student to compete in National Spelling Bee ...

Frets about how the new federal administration might affect prospects for vaccines were quelled at least somewhat by the U.S. FDA green light for Novavax Inc.’s COVID-19 vaccine Nuvaxovid, indicated ...